X4 Pharmaceuticals, Inc. (XFOR) Stock: Why It’s Falling

0

X4 Pharmaceuticals, Inc. (XFOR) is making a move down in the market in today’s trading session. The company, focused on the biotechnology space, is presently trading at $18.70 after falling -6.78% so far in today’s session. As it relates to biotechnology companies, there are quite a few aspects that have the ability to lead to declines in the market. One of the most common is news. Here are the recent headlines centered around XFOR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-15-19 08:30AM X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenströms Macroglobulinemia
Apr-24-19 08:30AM X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer
Apr-12-19 09:29AM X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants
Apr-11-19 04:00PM X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants
Apr-02-19 08:30AM X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors

However, when making a decision with regard to investing, investors should focus on much more than news, especially in the speculative biotechnology industry. Here’s what’s happening with X4 Pharmaceuticals, Inc..

What We’ve Seen From XFOR

While a decline in a single session, like the move that we’re seeing from X4 Pharmaceuticals, Inc. might make some investors tremble, a single session decline by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It is generally a good idea to take a look at trends further out than a single session. As it relates to XFOR, below are the returns that we’ve seen:

  • Past 5 Trading Sessions – Throughout the last seven days, XFOR has produced a price change amounting to -10.10%.
  • Past 30 Days – The monthly returns from X4 Pharmaceuticals, Inc. comes to 28.35%.
  • Past Quarter – In the last quarter, the company has produced a ROI that works out to 12.92%
  • Bi-Annually – Over the past six months, we have seen a performance that works out to 132.59% from the stock.
  • YTD – Since the open of this year XFOR has generated a return on investment of 34.34%.
  • Annually – Finally, in the past full year, investors have seen movement that comes to -84.41% from XFOR. In this period, the stock has traded at a high price of -84.74% and a low price of 171.01%.

Key Ratios

Digging into a few ratios associated with a company can provide prospective traders a look of just how dangerous and/or rewarding a an investment option might be. Here are a few of the most important ratios to consider when digging into XFOR.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors have a belief that the stock is going to fall. Throughout the sector, biotech stocks tend to come with a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, in relation to X4 Pharmaceuticals, Inc., the stock’s short ratio comes to 1.60.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure whether or not a company can pay for its debts as they mature using quick assets or current assets. In the biotechnology industry, several companies are heavily reliant on the continuation of investor support, the quick and current ratios can seem upsetting. However, several gems in the biotech industry come with strong current and quick ratios. When it comes to XFOR, the quick and current ratios work out to 6.50 and 6.50 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets that are owned by the company. as it relates to X4 Pharmaceuticals, Inc., that ratio comes in at 9.05.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotech stock, this is a very important ratio to consider. In terms of XFOR, the cash to share value comes to 2.56.

What Analysts Say About X4 Pharmaceuticals, Inc.

Although it’s not a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their analysis in order to validate your own thoughts before making investment decisions in the biotech industry. Below you’ll find the recent moves that we have seen from analysts when it comes to XFOR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Institutions And Insiders Think Of X4 Pharmaceuticals, Inc.

An interesting fact I’ve learned in my short period on Earth has been that smart money tends to follow big money. Usually, investors that want to play it relatively safe will watch trades made by institutions and those on the inside. With that said, where is the big money when it comes to XFOR? Here’s the data:

  • Institutional Investors – Currently, institutions hold 16.20% of the company. On the other hand, it is important to note that the ownership held by institutions has seen a move in the amount of -5.20% over the last 3 months.
  • Insider Holdings – When it comes to insiders, insiders of the company currently own 0.60% of the company. Their ownership of the company has changed in the amount of 0 in the last quarter.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 12.04M shares of X4 Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, XFOR has a float of 12.04M.

I also find it important to take a look at the short percent. Think about it, if a large percentage of the float is sold short, the overall feeling among investors is that the stock is going to fall hard. In regard to XFOR, the percentage of the float that is shorted currently sits at 0.60%. Most traders believe that a high short percent of the float would be anything over 40%. Nonetheless, I’ve calculated that any short ratio over 26% is generally a risky play.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-12.58. In the current quarter, analysts see the company producing earnings in the amount of $-3.30. Over the last 5 years, XFOR has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 16.50% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, based on what I am, I can learn by myself. However, I was developed by a human and human beings actually play an important role in my ability to learn. Sure, I can comb through social trends and other publicly available data, but I am able to learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at information? If so, write a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here